3-propyl-2-oxazolidinone | 58203-37-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 3-propyl-2-oxazolidinone
• 英文别名: 2-Propyl-2-oxazolidon；3-n-Propyl-2-oxazolidon；3-propyl-oxazolidin-2-one；3-Propyl-1,3-oxazolidin-2-one
• CAS: 58203-37-5
• 化学式: C₆H₁₁NO₂
• 分子量: 129.159
• InChiKey: KAMADDWOIUPNMK-UHFFFAOYSA-N

物化性质

• 沸点：
  80 °C(Press: 0.1 Torr)
• 密度：
  1.0846 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-propyl-2-oxazolidinone 、 3-羟基-N,N-二甲基苯胺 在 水 、 potassium hydroxide 作用下， 反应 10.0h， 生成 N,N-dimethyl-3-[2-(propylamino)ethoxy]aniline
  参考文献：
  名称：

  Me 3 SiCl促进的芳香化合物与N，O-缩醛束缚的分子内环化反应，可轻松制备1,4-苯并二氮杂pine骨架

  摘要：

  Me 3 SiCl促进的新型N，O-乙缩醛的分子内氨甲基化反应，是由N-烷基苯胺衍生物和N-烷基-2-恶唑烷酮通过容易的三步合成法制备的，可生产药学上有用的物质描述了具有各种官能团的1，4-苯并二氮杂skeleton骨架。此方法经7-成功地应用于两个三环苯并二氮杂衍生物的制备容易和1,4-苯并氧氮杂衍生物外切- trig的环化。

  DOI：

  10.1016/j.tet.2010.09.077
• 作为产物：
  描述：

  N-<2-Aethoxy-aethyl>-N-propyl-carbamoylchlorid 反应 0.5h， 生成 3-propyl-2-oxazolidinone
  参考文献：
  名称：

  Banks,R. et al., Journal of the Chemical Society. Perkin transactions I, 1975, p. 1836 - 1840

  摘要：

  DOI：

文献信息

• [EN] PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS<br/>[FR] COMPOSÉS DE PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
  申请人：LYSOSOMAL THERAPEUTICS INC

  公开号：WO2017176960A1

  公开（公告）日：2017-10-12

  The invention provides substituted pyrazolo[1,5-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrazolo[1,5-a]pyrimidinyl carboxamide compounds described herein include 2-heterocyclyl-4-alkyl-pyrazolo[1,5-a]pyrirnidine-3-carboxarnide compounds and variants thereof.

  本发明提供了取代的吡唑[1,5-a]嘧啶基甲酰胺及其相关有机化合物，包含此类化合物的组合物，医疗包，以及使用此类化合物和组合物治疗医疗障碍的方法，例如，戈谢病，帕金森病，路易体病，痴呆症或多系统萎缩症。所述的代表性的取代吡唑[1,5-a]嘧啶基甲酰胺化合物包括2-杂环基-4-烷基-吡唑[1,5-a]嘧啶-3-甲酰胺化合物及其变体。
• THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
  申请人：Popovici-Muller Janeta

  公开号：US20150087600A1

  公开（公告）日：2015-03-26

  Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

  提供了一种治疗具有IDH1/2突变等特征的癌症的方法，包括向需要的受试者施用本文描述的化合物。
• [EN] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH<br/>[FR] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES COMME INHIBITEURS D'IDH MUTANTE
  申请人：NOVARTIS AG

  公开号：WO2014141153A1

  公开（公告）日：2014-09-18

  The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are described herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant I DH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  这项发明涉及一种化学式(I)：或其药学上可接受的盐，其中R1、R2a、R2b和R3-R7如本文所述。该发明还涉及含有化合物化学式(I)的组合物，以及利用这些化合物抑制具有新型活性的突变IDH蛋白的用途。该发明还涉及利用化合物化学式(I)治疗与这种突变IDH蛋白相关的疾病或紊乱，包括但不限于细胞增殖紊乱，如癌症。
• SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS
  申请人：Bignan Gilles

  公开号：US20110294780A1

  公开（公告）日：2011-12-01

  The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

  本发明涉及式(I)的化合物，制备这些化合物的方法，组合物，中间体及其衍生物，并用于治疗包括但不限于强直性脊柱炎，动脉粥样硬化，关节炎（如类风湿关节炎，感染性关节炎，儿童关节炎，银屑病性关节炎，反应性关节炎），与骨相关的疾病（包括与骨形成有关的疾病），乳腺癌（包括对抗雌激素治疗无效的癌症），心血管疾病，软骨相关疾病（如软骨损伤/丧失，软骨退化以及与软骨形成有关的疾病），软骨发育不良，软骨肉瘤，慢性腰部损伤，慢性支气管炎，慢性炎症性气道疾病，慢性阻塞性肺疾病，糖尿病，能量稳态紊乱，痛风，假性痛风，脂质紊乱，代谢综合征，多发性骨髓瘤，肥胖，骨关节炎，遗传性骨发育不全，骨溶解性骨转移，软骨软化症，骨质疏松症，帕金森病，牙周病，多肌痛风，Reiter综合征，重复性应激损伤，高血糖，血糖水平升高和胰岛素抵抗等病症的方法。
• [EN] INHIBITORS OF LEUKOTRIENE PRODUCTION<br/>[FR] INHIBITEURS DE LA PRODUCTION DE LEUCOTRIÈNE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2015009611A1

  公开（公告）日：2015-01-22

  The present invention relates to aryl pyrazoles, and pharmaceutically acceptable salts thereof. The aryl pyrazoles of the present invention are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorders. The present invention also relates to pharmaceutical compositions comprising the aryl pyrazoles of the present invention, methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

  本发明涉及芳基吡唑及其药用可接受盐。本发明的芳基吡唑可用作白三烯A4水解酶（LTA4H）的抑制剂，并用于治疗与LTA4H相关的疾病。本发明还涉及包含本发明的芳基吡唑的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，以及制备这些化合物的方法。